Month: April 2026

TORONTO, April 20, 2026 (GLOBE NEWSWIRE) — Altus Group Limited (“Altus Group” or the “Company”) (TSX: AIF), a leading provider of commercial real estate (“CRE”) intelligence, announced today that, in connection with its ongoing substantial issuer bid (the “SIB”) to purchase for cancellation up to C$200,000,000 in value of its common shares (the “Shares”), the Ontario Securities Commission (the “OSC”), as Altus Group’s principal regulator, has granted an exemptive relief order exempting Altus Group from complying with certain extension take up, proportionate take up and related disclosure requirements. The SIB is being made by way of a “modified Dutch auction”, allowing shareholders who choose to participate in the SIB to tender Shares in three ways:by making an auction tender pursuant to which they agree to tender a specified...

Pharmacologic data highlight durable GI microbiome modulation, with improvement in epithelial barrier integrity, following SER-155 administration Additional presentations underscore the role of live biotherapeutics in shaping outcomes in IBD and immunocompromised patients CAMBRIDGE, Mass., April 20, 2026 (GLOBE NEWSWIRE) — Seres Therapeutics, Inc. (Nasdaq: MCRB) (Seres or the Company), a leading live biotherapeutics company, today announced three presentations at the 2026 European Society of Clinical Microbiology and Infectious Diseases (ESCMID) global congress, taking place April 17-21 in Munich, Germany. A poster presentation by Seres highlighted biomarker and clinical pharmacology data from the Company’s Phase 1b study of SER-155 (NCT04995653), evaluating changes in gastrointestinal (GI) microbiome composition following administration...

$100M bought deal financing with lead orders from EdgePoint and cornerstone investor Eric Sprott$105M Senior Secured Credit Facility with EdgePoint The Base Shelf Prospectus is accessible, and the Prospectus Supplement will be accessible, within two business days, through SEDAR+ All amounts in Canadian dollars unless otherwise noted VANCOUVER, British Columbia, April 20, 2026 (GLOBE NEWSWIRE) — New Found Gold Corp. (“New Found Gold” or the “Company”) (TSXV: NFG | NYSE American: NFGC) is pleased to announce a finance package consisting of (i) a $100M bought deal equity financing with lead orders from EdgePoint Investment Group Inc. (“EdgePoint”) and cornerstone investor Eric Sprott and (ii) a $105M senior secured credit facility with EdgePoint, for total gross proceeds of $205M. “We are pleased to announce this comprehensive finance...

Vancouver, Canada, April 20, 2026 (GLOBE NEWSWIRE) — Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind” or the “Company”), a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second generation psychedelic, neuroplastogen-derived therapeutics to solve major under-treated health problems, recently announced that CMND-100, the Company’s proprietary non-hallucinogenic MEAI-based oral drug candidate, for the treatment of Alcohol Use Disorder (AUD) has met the primary endpoint in its FDA-approved Phase I/IIa clinical trial. Results from the third cohort of the trial indicated a high safety profile for CMND-100, even at the higher dosage administered to date. The data demonstrated that the drug candidate was well tolerated, with no serious adverse events reported in the third...

ANN ARBOR, Mich., April 20, 2026 (GLOBE NEWSWIRE) — Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“the Company”, “Kraig Labs”, or “Kraig’s”), a world leader in spider silk technology*, today announced that it has begun processing nearly 1.8 metric tons of recombinant spider silk cocoons into finished reeled silk. In early April, the Company announced that it had exceeded 1.3 metric tons of cocoon production in March, setting a new production record. Since that announcement, Kraig Labs is now confirming that it produced an additional half ton of cocoons (approximately) that were not included in the March report. This brings the Company’s total available cocoon inventory to nearly 1.8 metric tons. The attached image represents less than 4% of the total cocoon production.Kraig Labs...

PETAH TIKVA, Israel, April 20, 2026 (GLOBE NEWSWIRE) — Gilat Satellite Networks Ltd. (NASDAQ: GILT, TASE: GILT), a worldwide leader in satellite networking technology, solutions, and services, today announced that it will release its first quarter 2026 financial results on Wednesday, May 13, 2026. Conference Call and Webcast Following the release, Adi Sfadia, Chief Executive Officer, and Gil Benyamini, Chief Financial Officer, will discuss Gilat’s first quarter 2026 results and business achievements and participate in a question and answer session:In English:  Date: Wednesday, May 13, 2026Start: 09:30 AM EST / 16:30 ISTA simultaneous webcast of the conference call will be available on the Gilat website at www.gilat.com and through this link: https://www.veidan-conferencing.com/gilatOr Dial-in:  US: 1-888-407-2553International: +972-3-918-0609The...

Rare Pediatric Disease Designation may render Pasithea eligible to receive a Priority Review Voucher (PRV) MIAMI, April 20, 2026 (GLOBE NEWSWIRE) — Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor, today announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation to PAS-004 for treatment of Neurofibromatosis type-1 (NF1). The FDA grants RPDD for serious or life-threatening diseases in which the serious or life-threatening manifestations primarily affect individuals aged from birth to 18 years and affect fewer than 200,000 people in the U.S. There are approximately 115,000 individuals in the U.S living with NF1. Under the FDA’s Rare Pediatric Disease Priority...

Elia to speak at the premier gathering of policy makers, industry leaders, and health experts between 11:30 AM ET – 12:00 PM ET on April 21 Event to be live streamed between 9:00 AM – 1:00 PM ETNEW HAVEN, Conn., April 20, 2026 (GLOBE NEWSWIRE) — Invivyd, Inc. (Nasdaq: IVVD) today announced that Marc Elia, Chairman of the Invivyd Board of Directors, is a featured speaker at the POLITICO Health Care Summit on Tuesday, April 21. During the session, Mr. Elia will frame the evolving landscape of viral disease prevention, including the role of monoclonal antibodies in keeping Americans healthy moving forward. “In American medicine, infectious disease prevention has historically involved substantial federal stewardship through the U.S. Department of Health and Human Services, including the U.S. Food and Drug Administration and the Centers...